CVE-2024-11120

Known Exploited Public Exploit
GeoVision EOL devices - OS Command Injection

Description

Certain EOL GeoVision devices have an OS Command Injection vulnerability. Unauthenticated remote attackers can exploit this vulnerability to inject and execute arbitrary system commands on the device. Moreover, this vulnerability has already been exploited by attackers, and we have received related reports.

Remediation

Solution:

  • The affected devices are no longer being maintained. It is recommended to replace them.

Category

9.8
CVSS
Severity: Critical
CVSS 3.1 •
EPSS 54.55% Top 5%
KEV Since 
Third-Party Advisory org.tw Third-Party Advisory org.tw Third-Party Advisory akamai.com
Affected: GeoVision GV-VS12
Affected: GeoVision GV-VS11
Affected: GeoVision GV-DSP_LPR_V3
Affected: GeoVision GVLX 4 V2
Affected: GeoVision GVLX 4 V3
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-11120?
CVE-2024-11120 has been scored as a critical severity vulnerability.
How to fix CVE-2024-11120?
To fix CVE-2024-11120: The affected devices are no longer being maintained. It is recommended to replace them.
Is CVE-2024-11120 being actively exploited in the wild?
It is confirmed that CVE-2024-11120 is actively exploited. Be extra cautious if you are using vulnerable components. According to its EPSS score, there is a ~55% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-11120?
CVE-2024-11120 affects GeoVision GV-VS12, GeoVision GV-VS11, GeoVision GV-DSP_LPR_V3, GeoVision GVLX 4 V2, GeoVision GVLX 4 V3.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.